NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis $1.39 +0.09 (+6.92%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.30▼$1.4250-Day Range$0.83▼$1.3952-Week Range$0.42▼$2.05Volume1.93 million shsAverage Volume1.71 million shsMarket Capitalization$343.08 millionP/E RatioN/ADividend YieldN/APrice Target$2.79 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Adaptimmune Therapeutics alerts: Email Address Adaptimmune Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside100.5% Upside$2.79 Price TargetShort InterestBearish2.55% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.26Based on 3 Articles This WeekInsider TradingSelling Shares$22,814 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.61) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector661st out of 936 stocksBiological Products, Except Diagnostic Industry107th out of 154 stocks 3.2 Analyst's Opinion Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAdaptimmune Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Adaptimmune Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.55% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently increased by 11.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAP. Previous Next 2.9 News and Social Media Coverage News SentimentAdaptimmune Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ADAP on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,814.00 in company stock.Percentage Held by Insiders12.44% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.Read more about Adaptimmune Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to grow in the coming year, from ($0.61) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 8.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adaptimmune Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Read More ADAP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADAP Stock News HeadlinesJuly 25 at 2:02 AM | insidermonkey.comWhy Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?July 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune on Revolutionary T-cell Therapy Prospects and Strong Sales ForecastJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 16, 2024 | americanbankingnews.comShort Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Increases By 15.1%July 3, 2024 | investorplace.com3 Biotech Moonshots With Imminent Catalyst PotentialMay 30, 2024 | globenewswire.comGalapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsMay 23, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cooper Co (COO), Neurocrine (NBIX) and Arcturus Therapeutics (ARCT)May 20, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday TradingJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 16, 2024 | msn.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call TranscriptMay 15, 2024 | investorplace.comADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | msn.comAdaptimmune Q1 2024 Earnings PreviewMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Fate Therapeutics (FATE) and Instil Bio (TIL)May 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)April 29, 2024 | finance.yahoo.comGlobal CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & PhaseApril 26, 2024 | seekingalpha.comAdaptimmune: Huge Opportunity Amid Their Setback With GenentechApril 26, 2024 | bizjournals.comGenentech parent Roche has cut 20% of risky drugs from pipeline and is adjusting its workforce to matchApril 24, 2024 | money.usnews.comAdaptimmune Therapeutics Plc - ADRSee More Headlines Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAP CUSIPN/A CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees490Year FoundedN/APrice Target and Rating Average Stock Price Target$2.79 High Stock Price Target$4.00 Low Stock Price Target$1.00 Potential Upside/Downside+100.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,870,000.00 Net Margins-890.13% Pretax Margin-883.39% Return on Equity-259.68% Return on Assets-61.31% Debt Debt-to-Equity RatioN/A Current Ratio2.81 Quick Ratio2.81 Sales & Book Value Annual Sales$60.28 million Price / Sales5.69 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book8.18Miscellaneous Outstanding Shares246,820,000Free Float216,120,000Market Cap$343.08 million OptionableOptionable Beta2.31 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Adrian G. Rawcliffe (Age 52)CEO, Principal Accounting Officer & Director Comp: $693.64kMr. Gavin Hilary James Wood ACA (Age 54)BA (Hons), Chief Financial Officer Comp: $508.22kMr. William C. Bertrand Jr. (Age 59)Esq., J.D., Chief Operating Officer Comp: $573.8kDr. Elliot Norry B.A. (Age 60)M.D., Chief Medical Officer Comp: $549.05kMs. Cintia Piccina Pharm.D. (Age 50)Chief Commercial Officer Comp: $597.44kDr. Helen Katrina Tayton-Martin MBA (Age 57)Ph.D., Co-Founder & Chief Business & Strategy Officer Comp: $709.84kMs. Joanna Brewer Ph.D. (Age 48)Chief Scientific Officer Dr. Juli P. Miller Ph.D.VP of Corporate Affairs & Investor RelationsMs. Kerry SharpSenior VP & General CouncilDana LynchSenior Director of Corporate CommunicationsMore ExecutivesKey CompetitorsPrecigenNASDAQ:PGENbluebird bioNASDAQ:BLUECellectisNASDAQ:CLLSAtara BiotherapeuticsNASDAQ:ATRACelyad OncologyNASDAQ:CYADView All CompetitorsInsiders & InstitutionsBaillie Gifford & Co.Sold 722,672 shares on 7/25/2024Ownership: 6.138%Cintia PiccinaSold 24,531 sharesTotal: $22,813.83 ($0.93/share)Baker BROS. Advisors LPSold 182,260 shares on 5/15/2024Ownership: 4.370%Boulder Hill Capital Management LPBought 90,800 shares on 5/14/2024Ownership: 0.037%GSA Capital Partners LLPSold 138,629 shares on 5/3/2024Ownership: 0.150%View All Insider TransactionsView All Institutional Transactions ADAP Stock Analysis - Frequently Asked Questions How have ADAP shares performed this year? Adaptimmune Therapeutics' stock was trading at $0.7930 on January 1st, 2024. Since then, ADAP stock has increased by 75.3% and is now trading at $1.39. View the best growth stocks for 2024 here. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics plc (NASDAQ:ADAP) released its quarterly earnings results on Wednesday, May, 15th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02. The biotechnology company earned $5.68 million during the quarter, compared to analysts' expectations of $4.40 million. Adaptimmune Therapeutics had a negative net margin of 890.13% and a negative trailing twelve-month return on equity of 259.68%. What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO? 6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are Adaptimmune Therapeutics' major shareholders? Top institutional investors of Adaptimmune Therapeutics include Baillie Gifford & Co. (6.14%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Gavin Wood, Garry E Menzel, Cintia Piccina, Adrian Rawcliffe, William C Bertrand Jr, John Lunger and Elliot Norry. View institutional ownership trends. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP) and Micron Technology (MU). This page (NASDAQ:ADAP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
